Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia

Young Ae Kang, Sung-Youn Kwon, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee, Young Ae Kang, Sung-Youn Kwon, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee

Abstract

Background/aims: We investigated the utility of serum C-reactive protein (CRP) and procalcitonin (PCT) for differentiating pulmonary tuberculosis (TB) from bacterial community-acquired pneumonia (CAP) in South Korea, a country with an intermediate TB burden.

Methods: We conducted a prospective study, enrolling 87 participants with suspected CAP in a community-based referral hospital. A clinical assessment was performed before treatment, and serum CRP and PCT were measured. The test results were compared to the final diagnoses.

Results: Of the 87 patients, 57 had bacterial CAP and 30 had pulmonary TB. The median CRP concentration was 14.58 mg/dL (range, 0.30 to 36.61) in patients with bacterial CAP and 5.27 mg/dL (range, 0.24 to 13.22) in those with pulmonary TB (p<0.001). The median PCT level was 0.514 ng/mL (range, 0.01 to 27.75) with bacterial CAP and 0.029 ng/mL (range, 0.01 to 0.87) with pulmonary TB (p<0.001). No difference was detected in the discriminative values of CRP and PCT (p=0.733).

Conclusions: The concentrations of CRP and PCT differed significantly in patients with pulmonary TB and bacterial CAP. The high sensitivity and negative predictive value for differentiating pulmonary TB from bacterial CAP suggest a supplementary role of CRP and PCT in the diagnostic exclusion of pulmonary TB from bacterial CAP in areas with an intermediate prevalence of pulmonary TB.

Keywords: C-reactive protein; Pneumonia, community acquired; Procalcitonin; Tuberculosis.

Figures

Figure 1
Figure 1
Receiver-operating characteristics curve for discriminating between pulmonary tuberculosis and bacterial community-acquired pneumonia for C-reactive protein (CRP) and procalcitonin (PCT). No difference was detected in the discriminative value between CRP and PCT.
Figure 2
Figure 2
C-reactive protein (CRP) and procalcitonin (PCT) concentration according to the pneumonia severity index in bacterial community-acquired pneumonia. Patients in risk classes III and V had a higher median PCT value compared to those in classes I and II, whereas no significant difference was observed in the CRP concentrations between those groups classified as Pneumonia Severity Index (PSI) I-II or PSI III-V.

References

    1. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis. 1994;18:501–513.
    1. Ishida T. Etiology of community-acquired pneumonia among adult patients in Japan. Jpn J Antibiot. 2000;53(Suppl B):3–12.
    1. Scott JA, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet. 2000;355:1225–1230.
    1. Liam CK, Pang YK, Poosparajah S. Pulmonary tuberculosis presenting as community-acquired pneumonia. Respirology. 2006;11:786–792.
    1. Kiyan E, Kilicaslan Z, Gurgan M, Tunaci A, Yildiz A. Clinical and radiographic features of pulmonary tuberculosis in non-AIDS immunocompromised patients. Int J Tuberc Lung Dis. 2003;7:764–770.
    1. Perez-Guzman C, Torres-Cruz A, Villarreal-Velarde H, Salazar-Lezama MA, Vargas MH. Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. Int J Tuberc Lung Dis. 2001;5:455–461.
    1. Lieberman D, Lieberman D, Schlaeffer F, Porath A. Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. Age Ageing. 1997;26:69–75.
    1. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487–48490.
    1. Almirall J, Bolibar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125:1335–1342.
    1. Kerttula Y, Leinonen M, Koskela M, Makela PH. The aetiology of pneumonia: application of bacterial serology and basic laboratory methods. J Infect. 1987;14:21–30.
    1. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection. 2000;28:68–73.
    1. Castro-Guardiola A, Armengou-Arxe A, Viejo-Rodriguez A, Penarroja-Matutano G, Garcia-Bragado F. Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward. Eur J Intern Med. 2000;11:334–339.
    1. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein: a clinical marker in community-acquired pneumonia. Chest. 1995;108:1288–1291.
    1. Ortqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis. 1995;27:457–462.
    1. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006;34:1996–2003.
    1. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39:206–217.
    1. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly. 2001;131:595–602.
    1. de Werra I, Jaccard C, Corradin SB, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med. 1997;25:607–613.
    1. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9–19.
    1. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93.
    1. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J. 2003;21:939–943.
    1. Lawn SD, Obeng J, Acheampong JW, Griffin GE. Serum procalcitonin concentrations in patients with pulmonary tuberculosis. Trans R Soc Trop Med Hyg. 1998;92:540–541.
    1. Schleicher GK, Herbert V, Brink A, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J. 2005;25:688–692.
    1. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250.
    1. World Health Organization. WHO Report 2007. Geneva: World Health Organization; 2007. Global Tuberculosis Control: Surveillance, Planning, Financing (WHO/HTM/TB/2007.376)
    1. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. BMJ. 2005;331:26.
    1. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
    1. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child. 2001;84:332–336.
    1. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–1812.
    1. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79:1605–1608.
    1. Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. 2002;34:895–901.
    1. Masia M, Gutierrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest. 2005;128:2223–2229.
    1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir